APPLICATION
ANDA201452
TYPE
ANDA
ORIGINAL APPROVAL
2021-05-21
LATEST ACTION
2026-06-15
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
LENALIDOMIDEPrescription
LENALIDOMIDE 2.5MG · CAPSULE · ORAL
LENALIDOMIDEPrescription
LENALIDOMIDE 15MG · CAPSULE · ORAL
LENALIDOMIDEPrescription
LENALIDOMIDE 5MG · CAPSULE · ORAL
LENALIDOMIDEPrescription
LENALIDOMIDE 20MG · CAPSULE · ORAL
LENALIDOMIDEPrescription
LENALIDOMIDE 25MG · CAPSULE · ORAL
LENALIDOMIDEPrescription
LENALIDOMIDE 10MG · CAPSULE · ORAL
Approval history
2026-06-15Labeling · Supplement 3 · standardAP
2026-06-15Labeling · Supplement 4 · standardAP
2026-04-27REMS · Supplement 11AP
2023-03-24REMS · Supplement 6AP
2023-03-06UNKNOWN · OriginalAP
2021-08-05REMS · Supplement 1AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.